.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Chubb
QuintilesIMS
Teva
Fish and Richardson
Moodys
Queensland Health
AstraZeneca
Healthtrust
Mallinckrodt

Generated: November 20, 2017

DrugPatentWatch Database Preview

Details for Patent: RE39706

« Back to Dashboard

Summary for Patent: RE39706

Title:Crystalline form of a vitamin D analogue
Abstract:The present invention relates to calcipotriol hydrate--a new crystalline form of calcipotriol--with superior technical properties and with superior stability.
Inventor(s): Hansen; Erik Torngaard (Hundested, DK), Andersen; Niels Smidt Rastrup (Vanlose, DK), Ringborg; Lene Hoffmeyer (Bronshoj, DK)
Assignee: Leo Pharma A/S (Ballerup, DK)
Application Number:10/986,575
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Formulation;

No matches for this query

Foreign Priority and PCT Information for Patent: RE39706

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9300763Jan 15, 1993
PCT Information
PCT FiledJanuary 15, 1993PCT Application Number:PCT/DK94/00011
PCT Publication Date:July 21, 1994PCT Publication Number: WO94/15912

International Patent Family for Patent: RE39706

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria159717► Subscribe
Australia5857394► Subscribe
Australia663249► Subscribe
Canada2151730► Subscribe
China1040746► Subscribe
China1115979► Subscribe
Germany69406529► Subscribe
Denmark0679154► Subscribe
European Patent Office0679154► Subscribe
Spain2111287► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
UBS
McKinsey
Medtronic
Merck
Novartis
Johnson and Johnson
Daiichi Sankyo
Cantor Fitzgerald
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot